Genentech and Roche present trontinemab, RG6434 and Elecsys pTau data at CTAD 2026
- 16 abstracts accepted for CTAD including two symposia and two oral presentations.
- Phase III PrevenTRON in preclinical Alzheimer’s disease has started enrolling participants.
- Phase II TARBELA-AD launched to evaluate oral NLRP3 inhibitor RG6434 in early symptomatic Alzheimer’s disease.
- Phase Ib/IIa Brainshuttle study data show rapid amyloid clearance dynamics with trontinemab; Elecsys pTau217 and pTau181 blood-test data support diagnostic use and economic evaluations.
CTAD participation
Genentech and Roche will present 16 abstracts at the 19th CTAD Congress (November 16–19, 2026), including two scientific symposia, two oral presentations and multiple posters covering pharmaceuticals and diagnostics.
Pharmaceutical portfolio updates
Trontinemab: Phase Ib/IIa Brainshuttle AD data will report neuroimaging, pharmacokinetics/pharmacodynamics and safety findings, including 89Zr PET measures of brain delivery and rapid amyloid clearance dynamics. The Phase III PrevenTRON study in cognitively unimpaired, biomarker‑positive individuals has started enrollment and will be detailed in an oral presentation.
RG6434 (NLRP3 inhibitor): Genentech and Roche have initiated TARBELA‑AD, a randomized, double‑blind, placebo‑controlled Phase II trial evaluating the oral NLRP3 inhibitor RG6434 in early symptomatic Alzheimer’s disease to test a neuroinflammation‑targeting mechanism alongside amyloid‑directed approaches.
Diagnostics and implementation data
Roche will present new clinical, health‑economic and real‑world analyses for Elecsys pTau217 and pTau181 plasma assays, including validation of cutoffs across care settings and populations (Asian and Chinese cohorts), economic models for primary and specialist care in the U.S. and Canada, and utilization studies (ROAD‑US) assessing implementation in community practice.
Selected sessions
Key sessions include a symposium on Brainshuttle imaging (Nov 16), a symposium on NLRP3 and neuroinflammation (Nov 17), a keynote on diagnostics and prevention (Nov 17) and an oral on PrevenTRON study design (Nov 18), plus multiple poster and ePoster presentations on assay validation, economics and trial‑design topics.
Source: Genentech